Moreover, a double-blind, placebo-controlled trial enrolling patients from 116 research centers showed that Dapa decreases the urine albumin-to-creatinine ratio and slows kidney disease progression in patients with moderate-to-severe CKD (Pollock et al., 2019). This evidence concerns the gene ALB and chronic kidney disease.